TOPICAL FORMULATION TO IMPROVE HYPERPIGMENTATION 281 better tolerability, as well as reduced redness and irritation relative to HQ4%. This prod- uct has been found to be safe and effective for use in hyperpigmentation. R EFERENCES (1) N. A. Vashi and R. V. Kundu, Facial hyperpigmentation: causes and treatment, Br. J. Dermatol., 169(Suppl 3), 41–56 (2013). (2 ) D. Rigopoulos, S. Gregoriou, and A. Katsambas, Hyperpigmentation and melasma, J. Cosmet. Dermatol., 6, 195–202 (2007). (3 ) A. K. Gupta, M. D. Gover, K. Nouri, and S. Taylor, The treatment of melasma: a review of clinical tri- als, J. Am. Acad. Dermatol., 55, 1048–1065 (2006). (4 ) S. Yanagishita-Nakatsuji, K. Fukai, A. Ohyama, A. Umekoji, J. Sowa-Osako, and D. Tsuruta, Probable allergic contact dermatitis from hydroquinone presenting as leukomelanoderma: report of two cases, J. Dermatol., 44, e330–e331 (2017). (5) S. N. Mishra, R. S. Dhurat, D. J. Deshpande, and C. S. Nayak, Diagnostic utility of dermatoscopy in hydroquinone- induced exogenous ochronosis, Int. J. Dermatol., 52, 413–417 (2013). (6 ) F. W. Kari, J. Bucher, S. L. Eustis, J. K. Haseman, and J. E. Huff, Toxicity and carcinogenicity of hy- droquinone in F344/N ratsand B6C3F1 mice, Food Chem. Toxicol., 30, 737–747 (1992). (7 ) T. Tsutsui, N. Hayashi, H. Maizumi, J. Huff, and J. C. Barrett, Benzene-, catechol-, hydroquinone- and phenol-induced cell transformation, gene mutations, chromosome aberrations, aneuploidy, sister chroma- tid exchanges and unscheduled DNA synthesis in Syrian hamster embryo cells, Mutat. Res., 373, 113–123 (1997). (8 ) M. H. Yu and S. O. Lee, Hydroquinone stimulates cell invasion through activator protein-1-dependent induction of MMP-9 in HepG2 human hepatoma cells, Food Chem. Toxicol., 89, 120–125 (2016). (9) V. M. Sheth and A. G. Pandya, Melasma: a comprehensive update: part II, J. Am. Acad. Dermatol., 65, 699–714 (2011). (1 0) N. Atefi , B. Dalvand, M. Ghassemi, G. Mehran, and A. Heydarian, Therapeutic effects of topical tranexamic acid in comparison with hydroquinone in treatment of women with melasma. Dermatol. Ther (Heidelb)., 7, 417–424 (2017). (1 1) M. Banihashemi, N. Zabolinejad, M. R. Jaafari, M. Salehi, and A. Jabari, Comparison of therapeutic effects of liposomal tranexamic acid and conventional hydroquinone on melasma, J. Cosmet. Dermatol., 14, 174–177 (2015). (1 2) M. S. Janney, R. Subramaniyan, R. Dabas, S. Lal, N. M. Das, and S. K. Godara, A randomized controlled study comparing the effi cacy of topical 5% tranexamic acid solution versus 3% hydroquinone cream in melasma, J. Cutan. Aesthetic Surg., 12, 63–67 (2019). (1 3 ) B. Ebrahimi and F. F. Naeini, Topical tranexamic acid as a promising treatment for melasma, J. Res. Med. Sci., 19, 753–757 (2014). (1 4 ) M. Martínez-Esparza, C. Ferrer, M. T. Castells, J. C. García-Borrón, and A. Zuastiand, Transforming growth factor beta1 mediates hypopigmentation of B16 mouse melanoma cells by inhibition of melanin formation and melanosome maturation, Int. J. Biochem. Cell Biol., 33, 971–983 (2001). (15) M. Brenner and V. J. Heari n g, Modifying skin pigmentation - approaches through intrinsic biochemis- try and exogenous agents, Drug Discov. Today Dis. Mech., 5, e189–e199 (2008). (16) H. Kim, H. R. Choi, D. S. K im, and K. C. Park, Topical hypopigmenting agents for pigmentary disor- ders and their mechanisms of action, Ann. Dermatol., 24, 1–6 (2012). (17) G. H. Park, Y. Rhee do, H. R. Moon, C. H. Won, M. W. Lee, J. H. Choi, K. C. Moon, and S. E. Chang, Effect of an epidermal growth factor-containing cream on postinfl ammatory hyperpigmentation after Q-switched 532-nm neodymium-doped yttrium aluminum garnet laser treatment, Dermatol. Surg., 41, 131–135 (2015). (18) D. Steiner, C. Feola, N. B i aleski, F. A. Silva, A. C. P. Antiori, F. Addor, and B. B. Folino, Study evaluat- ing the effi cacy of topical and injected tranexamic acid in treatment of melasma, Surg. Cosmet. Dermatol., 1, 174–177 (2009). (19) P. Kanechorn Na Ayuthaya, N . Niumphradit, A. Manosroi, and A. Nakakes, Topical 5% tranexamic acid for the treatment of melasma in Asians: a double-blind randomized controlled clinical trial, J. Cosmet. Laser Ther., 14, 150–154 (2012). (20) S. J. Kim, J. Y. Park, T. S hibata, R. Fujiwara, and H. Y. Kang, Effi cacy and possible mechanisms of topical tranexamic acid in melasma. Clin. Exp. Dermatol., 41, 480–485 (2016).

JOURNAL OF COSMETIC SCIENCE 282 (21) P. E. Grimes, Management o f hyperpigmentation in darker racial ethnic groups, Semin. Cutan. Med. Surg., 28, 77–85 (2009). (22) L. E. Espinal-Perez, B. Mo n cada, and J. P. Castanedo-Cazares, A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma, Int. J. Dermatol., 43, 604–761 (2004). (23) P. K. Farris, Topical vita m in C: a useful agent for treating photoaging and other dermatologic condi- tions, Dermatol. Surg., 31, 814–818 (2005). (24) Z. D. Draelos, Skin lighte n ing preparations and the hydroquinone controversy. Dermatol. Ther., 20, 308–313 (2007). (25) J. Navarrete-Solís, J. P. C astanedo-Cázares, B. Torres-Álvarez, C. Oros-Ovalle, C. Fuentes-Ahumada, F. J. González, J. D. Martínez-Ramírez, and B. Moncada, A double-blind, randomized clinical trial of niacina- mide 4% versus hydroquinone 4% in the treatment of melasma, Dermatol Res Pract, 2011, 379173 (2011). (26) M. Taraz, S. Niknam, and A. H. Ehsani, Tranexamic acid in treatment of melasma: a comprehensive r eview of clinical studies, Dermatol. Ther., 30, 1–8 (2017). (27) W. J. Yun, S. H. Bang, K. H. Min, S. W. Kim, M. W. Lee, and S. E. Chang, Epidermal growth factor a nd epidermal growth factor signaling attenuate laser-induced melanogenesis, Dermatol. Surg., 39, 1903–1911 (2013). (28) A. Lyons, J. Stoll, and R. Moy, A randomized, double-blind, placebo-controlled, split-face study o f the effi cacy of topical epidermal growth factor for the treatment of melasma, J. Drugs Dermatol., 17, 970– 973 (2018). (29) W. O. Pratchyapurit, Combined use of two formulations containing diacetyl boldine, TGF-β1 biomi- me t ic oligopeptide-68 with other hypopigmenting/exfoliating agents and sunscreen provides effective and convenient treatment for facial melasma. Either is equal to or is better than 4% hydroquinone on normal skin. J. Cosmet. Dermatol., 15, 131–144 (2016). (30) H. Choi, S. Ahn, B. G. Lee, I. Chang, and J. S. Hwang, Inhibition of skin pigmentation by an extract of Lepidium apetalum and its possible implication in IL-6 mediated signaling, Pigment Cell Res. 18, 439–446 (2005). (31) Y. I. Yamaguchi, A. Morita, A. Maeda, and V. J. Hearing, Regulation of skin pigmentation and thick- ness by Dickkopf 1 (DKK1), J. Inv e st. Dermatol. Symp. Proc., 14, 73–75 (2009). (32) Y. Yamaguchi, T. Passeron, H. Watabe, K. Yasumoto, F. Rouzaud, T. Hoashi, and V. J. Hearingand, The effects of dickkopf 1 on gene expression and Wnt signaling by melanocyt e s: mechanisms underlying its suppression of melanocyte function and proliferation, J. Invest. Dermatol., 127, 1217–1225 (2007). (33) T. Hakozaki, L. Minwalla, J. Zhuang, M. Chhoa, A . Matsubara, K. Miyamoto, A Greatens, G. G. Hillebrand, D. L. Bissett, and R. E. Boissyand, The effect of niacinamide on reducing cutaneous pig- mentation and suppression of melanosome transfer, Br. J. Dermatol., 147, 20–31 (2002). (34) H. L. Gensler, Prevention of photoimmunosuppression and photocarcinoge n esis by topical nicotin- amide, Nutr. Canc., 29, 157–162 (1997). (35) A. R. Shalita, J. G. Smith, L. C. Parish, M. C.S Sofman, and, D. K. Chalker, Topical nicotinamide com- pared with clindamycin gel in the treatment of infl ammatory acne vulgaris, Int. J. Dermatol., 34, 434– 437 (1995). ( 36) A. Wozniacka, M. Wieczorkowska, J. Gebicki, and A. Sysa-Jedrzejowska, Topical application of 1-methylnicotinamide in the treatment of rosacea: a pilot study, Clin. Exp. Dermatol., 30, 632–635 (2005). (37) D. Levine, Z. Even-Chen, I. Lipets, O. A. Pritulo, T. V. Svyatenko, Y. Andrashko, M. Lebwohl, and A. Gottlieb, Pilot, multicenter, double-blind, ran d omized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis, J. Am. Acad. Dermatol., 63, 775–781 (2010). (38) W. Zhu and J. Gao, The use of botanical extracts as topical skin-lightening agents for the improvement of skin pigmentation disorders, J. Invest. Dermatol. Symp. Proc., 13, 20–24 (2008). (39) V. D. Callender, S. St Surin-Lord, E. C. Davis, and M. Maclin, Postinfl ammatory hyperpigmentation: etiologic and therapeutic considerations, Am. J. Clin. Dermato l ., 12, 87–99 (2011). (40) I. Majid, I. Haq, S. Imran, A. Keen, K. Aziz, and T. Arif, Proposing melasma severity index: a new, more practical, offi ce-based scoring system for assessing the sev e rity of melasma, Indian J. Dermatol., 61, 39–44 (2016). (41) D. A. Abou-Taleb, A. K. Ibrahim, E. M. Youssef, and A. E. Moubasher, Reliability, validity, and sensi- tivity to change overtime of the modifi ed melasma area and severity index score. Dermatol. Surg., 43, 210–217 (2017).